Renibus Therapeutics

Apr 24, 2025

Renibus Therapeutics Announces Completion of Enrollment in PROTECT, a Pivotal Phase 3 Clinical Trial of RBT-1 to Reduce the Risk of Post-Operative Complications After Cardiac Surgery

Feb 05, 2025

Renibus to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Sep 24, 2024

Renibus Therapeutics Announces Participation at Upcoming Investor Conferences

Apr 26, 2024

Renibus Therapeutics Announces Oral Presentations on RBT-1 at AATS and SCA Medical Conferences

Apr 18, 2024

Renibus Therapeutics Announces Oral Presentation on RBT-1 at the European Association for Cardio-Thoracic Surgery (EACTS) 2nd Innovation Summit

Apr 02, 2024

Renibus Announces Participation at the 23rd Annual Needham Virtual Healthcare Conference

Mar 21, 2024

Renibus Announces Leadership Transition

Feb 22, 2024

Renibus Therapeutics to Present at the Evercore ISI 2024 Emerging Biotech Conference

Feb 07, 2024

Renibus Therapeutics Announces Presentation at Oppenheimer 34th Annual Healthcare Conference

Jan 09, 2024

Renibus Announces Publication of Results from Phase 2 Study Evaluating RBT-1 as a Pre-Conditioning Agent to Reduce Post-Operative Complications Following Cardiothoracic Surgery